Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that its Chairman and CEO, Craig Dees, Ph.D., will be participating in several investment community events over the next two months.
- Dr. Dees will host a breakfast meeting on July 23 at 10:30 A.M. in Cleveland, OH at the Doubletree Hotel Cleveland South, the Amphitheatre Room, 6200 Quarry Lane, Independence, Ohio.
- Dr. Dees will present at the InvestEd 2008 Conference in Charlotte, NC, from August 8-10 at the Hilton Charlotte University Place Hotel, 8629 J.M. Keynes Drive.
- Dr. Dees will participate at the Red Chip Small-Cap Investor Conference on Thursday, August 21 at the New York Marriott Marquis Hotel, 1535 Broadway, New York.
Dr. Dees said, "As Provectus continues to make significant strides in developing our oncological and dermatological therapies, we continue to strive to increase investor awareness and visibility of the Company. We are especially excited because of the progress we have been making in opening a new front in the war on cancer. We are looking forward to telling all of the attendees the Provectus story."
Craig Dees, Ph.D., has spent more than 20 years in senior management positions at Provectus Pharmaceuticals, Inc.; Photogen Technologies, Inc.; the Oak Ridge National Laboratory; LipoGen, Inc.; and TechAmerica, Inc. Dees was a founder, senior scientist and founding director of Photogen before Provectus was formed. His responsibilities have included product design and development in the fields of ethical vaccines, cosmetics, human diagnostics and over-the-counter pharmaceuticals. Dees holds a Ph.D. in molecular virology from the University of Wisconsin. He earned his Master of Science degree in immunology from Auburn University, and his bachelor's degree in microbiology from Brigham Young University.
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc. via the information provided above.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
